s. Both drugs are substrates and inhibitors of the drug transporter P-glycoprotein (P-gp). In addition, verapamil is an inhibitor of the hepatic enzyme CYP3A4. Velpatasvir is a CYP3A4 substrate.
Trimethoprim: Use caution when administering velpatasvir with trimethoprim. Taking these drugs together may increase velpatasvir plasma concentrations, potentially resulting in adverse events. Velpatasvir is a CYP2C8 substrate; trimethoprim is an inhibitor of CYP2C8.
Valproic Acid, Divalproex Sodium: Theoretically, taking velpatasvir with valproic acid may reduce the plasma concentrations of velpatasvir, potentially resulting in loss of antiviral efficacy. Caution is advised if these drugs are administered together. Velpatasvir is a substrate of the drug transporter P-glycoprotein (P-gp); valproic acid is a weak P-gp inducer. Velpatasvir is also a substrate for CYP3A4; valproic acid is a weak inducer/inhibitor of CYP34.
Vandetanib: Use caution if coadministration of vandetanib with sofosbuvir is necessary, due to a possible increase in sofosbuvir-related adverse reactions. Sofosbuvir is a substrate of P-glycoprotein (P-gp). Coadministration with vandetanib increased the Cmax and AUC of digoxin, another P-gp substrate, by 29% and 23%, respectively. In clinical trials, no clinically significant interaction was noted when sofosbuvir was administered with darunavir/ritonavir (P-gp inhibitors); according to the manufacturer, sofosbuvir may be coadministered with P-gp inhibitors.
Vemurafenib: Use caution when administering velpatasvir with vemurafenib. Taking these medications together may increase the plasma concentrations of both drugs, potentially resulting in adverse events. Both drugs are substrates and inhibitors of the drug transporters P-glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP).
Verapamil: Use caution when administering velpatasvir with verapamil. Taking these medications together may increase the plasma concentrations of both drugs, potentially resulting in adverse events. Both drugs are substrates and inhibitors of the drug transporter P-glycoprotein (P-gp). In addition, verapamil is an inhibitor of the hepatic enzyme CYP3A4. Velpatasvir is a CYP3A4 substrate.
Vilazodone: Use caution when administering velpatasvir with vilazodone. Taking these drugs together may increase velpatasvir plasma concentrations, potentially resulting in adverse events. Velpatasvir is a CYP2C8 substrate; vilazodone is an inhibitor of CYP2C8.
Vismodegib: Use caution when administering velpatasvir with vismodegib. Taking these drugs together may increase the plasma concentrations of velpatasvir, potentially resulting in adverse events. Velpatasvir is a substrate of the Breast Cancer Resistance Protein (BCRP); vismodegib is an inhibitor of BCRP.
Voriconazole: Use caution when administering velpatasvir with voriconazole. Taking these drugs together may increase velpatasvir plasma concentrations, potentially resulting in adverse events. Voriconazole is a CYP3A4 inhibitor; velpatasvir is a substrate of CYP3A4.
Zafirlukast: Use caution when administering velpatasvir with zafirlukast. Taking these drugs together may increase velpatasvir plasma concentrations, potentially resulting in adverse events. Velpatasvir is a CYP3A4 substrate; zafirlukast is an inhibitor of CYP3A4.
Zonisamide: Use caution when administering velpatasvir with zonisamide. Taking these drugs together may increas |
